Andrew N. Schiff - 02 Jun 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 02 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 06 Jun 2022, 17:36:48 UTC
Previous filing: 23 Jun 2021
Next filing: 16 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+3,356	+21%		19,565	03 Jun 2022	Direct	F1
holding	ACRS	Common Stock						634,455	02 Jun 2022	By Aisling Capital IV LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Stock Option (Right to Buy)	Award	$0	+15,750		$0.000000	15,750	02 Jun 2022	Common Stock	15,750	$14.48	Direct	F3, F4
transaction	ACRS	Restricted Stock Units	Award	$0	+4,507		$0.000000	4,507	02 Jun 2022	Common Stock	4,507		Direct	F1, F3, F5
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-3,356	-100%	$0.000000^*	0	03 Jun 2022	Common Stock	3,356		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3	This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.
F4	The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date.
F5	The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
F6	The shares underlying these restricted stock units vested on June 3, 2022.